Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eris LifesciencesBOM:540596 +0.88%92 PB Ratio is 5.20 as of Jul. 21, 2026, which is 1% below its 10-year median of 5.26. GuruFocus rates BOM:540596 with a GF Score™ of 92/100 and a GF Value™ of ₹1,653.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 924 Drug Manufacturers companies, Eris Lifesciences ranks worse than 83.33% on this metric.
Eris Lifesciences Ltd stock PB Ratio (=5.15) is close to 2-year low of 4.7.
The historical rank and industry rank for Eris Lifesciences's PB Ratio or its related term are showing as below:
BOM:540596'
s PB Ratio Range Over the Past 10 Years
Min: 3.54 Med: 5.26 Max: 14.89
Current: 5.2
During the past 13 years, Eris Lifesciences's highest PB Ratio was 14.89. The lowest was 3.54. And the median was 5.26.
BOM:540596's PB Ratio is ranked worse than 83.33% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.895
vs BOM:540596: 5.20
During the past 12 months, Eris Lifesciences's average Book Value Per Share Growth Rate was 34.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 20.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 24.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Eris Lifesciences was 53.10% per year. The lowest was 14.30% per year. And the median was 22.80% per year.
Back to Basics: PB Ratio
Eris Lifesciences (BOM:540596) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Eris Lifesciences PB Ratio Related Terms
Eris Lifesciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Eris Lifesciences (BOM:540596) has a PB Ratio of 5.20 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eris Lifesciences and its competitors. This is near median its historical median of 5.26. Over the past decade, Eris Lifesciences' PB Ratio has ranged from 3.54 to 14.89. According to the industry distribution chart, Eris Lifesciences ranks #770 out of 924 companies in the Drug Manufacturers industry, placing it in the top 83.3%.
Is Eris Lifesciences' PB Ratio too high?
Eris Lifesciences' current PB Ratio of 5.20 is near median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 3.54 to a high of 14.89. The Drug Manufacturers industry median PB Ratio is 1.90. Eris Lifesciences' value of 5.20 is 174.4% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #770 out of 924 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eris Lifesciences has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #770 out of 924 companies for PB Ratio. This places Eris Lifesciences in the lower half of its industry. The industry median PB Ratio is 1.90. Eris Lifesciences' value of 5.20 is 174.4% above this benchmark. Historically, Eris Lifesciences' own PB Ratio has ranged from 3.54 to 14.89 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 1.90, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current PB Ratio of 5.20 is 174.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current PB Ratio is 5.20, which is near median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,653.63, compared to a current price of ₹1,464.00 — trading 11.5% below its estimated fair value. The current PB Ratio is 5.20, which is near median its 10-year median of 5.26 and 174.4% above the Drug Manufacturers industry median of 1.90. Eris Lifesciences' overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current PB Ratio is 5.20 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,464.00 is trading 11.5% below its estimated GF Value™ of ₹1,653.63.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
PB Ratio: 5.20 (near median its 10-year median of 5.26)
GF Value™: ₹1,653.63 vs. price of ₹1,464.00 (11.5% below fair value)
Industry Position: 174.4% above the Drug Manufacturers median (#770 of 924)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
92GF Score
Get the complete analysis for BOM:540596
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
